在治疗肝肠球菌的新药治疗方面取得进展
Yunzhang Li1, Nana Xie1, Jinping Chai2
1Clinical Medical College of Qinghai University, Xining, China.
阿尔本达是治疗球菌的主要药物,但也有缺点. 新的研究探讨了改性胺醇,向疗法,组合策略和天然药物,以提高治疗疗效和患者坚持治疗.
科学领域:
- 寄生虫学的寄生虫学
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
背景情况:
- 脊髓灰质炎是一种动物性寄生虫病,需要有效的治疗.
- 目前的标准治疗包括手术和阿尔本达.
- 阿尔本达面临的挑战包括生物可用性低,溶解性差,治疗时间长,以及不良影响,影响患者的坚持和疗效.
研究的目的:
- 审查最近在抗球菌病药物开发方面的进展.
- 探索超越传统阿尔本达治疗的新型治疗策略.
主要方法:
- 对新型抗球菌病药物的研究进行系统审查.
- 对研究的分析,重点是结构修改和新配方的西米达药物.
- 检查针对性药物治疗,联合药物治疗策略和天然药物的研究.
主要成果:
- 在开发新的抗球菌病药物方面取得了重大进展.
- 研究领域包括改性胺醇,向疗法,组合疗法和天然产品衍生药物.
结论:
- 新药开发战略旨在克服阿尔本达的局限性.
- 未来的治疗可能涉及改进的胺醇配方,有针对性的方法,组合疗法和自然药物衍生剂,以更好地管理球菌.
更多相关视频
07:54Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy
Published on: December 15, 2011
09:02Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatic Drug Excretion: Influencing Factors
Hepatic Drug Clearance: Role of Transporters
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
Most drugs undergo restrictive clearance, which is proportional to the...
